/

TGTX

TG Therapeutics, Inc.Open

54.32−0.95 −1.72%USD

NasdaqCM · as of Oct 13, 10:17 ET · 15m delay

Open

55.23

Prev close

55.27

Day range

54.0555.32

52-week range

26.7659.30

Volume

110.62K0.06×

Mkt cap

8.32B

P/E ttm

19.75

Fwd P/E

20.06

EPS ttm

2.75

Div yield

0.00%

Earnings

Aug 3, 2026

From 52w high

−8.40%

Price Chart

Yahoo Finance · delayed

TGTXOct 13, 2026O 55.23H 55.32L 54.05C 54.32−0.95 (−1.72%)Vol 110.62K

SMA 5053.82
SMA 20042.12

1Y change +60.90% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

TGTX TG Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +4.08%
1 month: +0.80%
3 months: −1.04%
6 months: +57.18%
Year to date: +82.22%
1 year: +58.74%

Valuation & ownership

Market cap: 8.32B
Enterprise value: 8.04B
P/E (ttm): 19.75
Forward P/E: 20.06
PEG ratio: 1.61
Price / book: 12.76
Price / sales (ttm): 10.40
EV / EBITDA: 58.94
EPS (ttm): 2.75
EPS (forward): 2.71
Beta (5y monthly): 1.80
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 153.08M
Float: 135.24M
Short % of float: 28.93%
Short ratio (days): 16.50
Held by insiders: 7.47%
Held by institutions: 74.70%
Avg volume (3m): 2.00M
50-day average: 53.65
200-day average: 42.01
52-week change: +58.74%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 48.4
vs 50-day SMA: +0.93%
vs 200-day SMA: +28.95%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 3.84%
Realised vol (20d, ann.): 37.3%
From 52-week high: −8.40%
From 52-week low: +102.99%

ANR

Analyst Consensus

7 analysts

Consensus

Strong buy

1.50 on a 1 (strong buy) – 5 (sell) scale

Mean target

69.71

+28.34% implied

Low 21.00Median 75.00High 86.00

Recommendation trend

Now7 / 0 / 1
1m ago7 / 0 /

DES

About TG Therapeutics, Inc.

Yahoo Finance profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Sector: Healthcare
Industry: Biotechnology
Employees: 399
Headquarters: Morrisville, NC, United States
Website: tgtherapeutics.com
Officers: Mr. Michael S. Weiss Esq., J.D. Chairman, CEO & President
Mr. Sean A. Power CPA CFO, Corporate Secretary & Treasurer

SEAS

Seasonality · TGTX

2010–2026 · monthly returns

Strongest month Jan +22.34%Weakest month Oct −9.24%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-1.3	2.2	10.4	1.7	12.3	44.8	-5.3	4.4	2.7	-2.6			+82.2%
2025	5.3	-5.1	31.0	15.4	-22.9	2.5	-1.4	-17.4	23.2	-3.7	-4.4	-10.4	−1.0%
2024	-4.9	6.0	-11.7	-10.2	19.3	9.1	11.1	18.9	-0.4	7.1	38.9	-13.5	+76.2%
2023	28.7	5.2	-6.1	65.1	7.2	-6.7	-16.7	-49.4	-20.2	-7.5	65.7	33.3	+44.4%
2022	-39.1	-14.7	-3.6	-27.0	-36.3	-3.8	40.9	19.0	-17.0	-1.7	51.5	34.1	−37.7%
2021	-7.2	-9.3	10.1	-7.2	-22.0	11.2	-9.8	-22.6	22.9	-6.2	-51.3	25.0	−63.5%
2020	28.0	-11.7	-21.6	19.5	58.6	4.5	0.5	26.7	7.9	-5.6	16.1	77.3	+368.6%
2019	0.0	65.9	18.2	-1.1	-21.1	38.0	-13.4	-17.1	-9.6	21.6	19.9	35.5	+170.7%
2018	40.2	21.7	1.4	1.1	-6.6	-1.9	-10.6	8.1	-55.9	-18.7	10.8	-18.7	−50.0%
2017	3.2	18.7	104.4	-5.2	1.8	-10.7	14.4	10.4	-6.7	-31.2	5.5	-4.7	+76.3%
2016	-31.5	2.0	2.3	6.9	-17.5	-19.4	-2.5	7.4	21.9	-30.9	7.5	-19.1	−61.0%
2015	-10.1	1.9	6.7	-9.8	12.8	5.4	5.2	-29.6	-17.9	22.7	6.5	-9.5	−24.7%
2014	53.8	10.0	4.5	-22.8	22.5	43.8	-15.8	7.2	25.8	3.0	35.8	6.2	+306.2%
2013	1.9	3.5	40.6	0.0	18.5	-0.2	-4.4	-1.5	-16.3	-28.4	22.2	-11.6	+7.1%
2012	200.0	183.3	-29.4	-8.1	4.8	-3.8	0.0	-60.0	-10.0	-6.2	-0.5	73.3	+223.6%
2011	66.7	-36.7	-26.3	7.1	-13.3	-53.8	-13.3	-34.6	-35.3	-45.5	0.0	-66.7	−97.8%
2010						-30.8	0.0	-11.1	-25.0	-16.7	-20.0	-10.0	−72.3%

INSD

Insider Activity · TGTX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

6K shares

Sells, 6 months

5K shares

Net shares

+1.1K

Net change in insider shares

0.00%

Date	Insider	Transaction	Shares	Value
Sep 9, 2026	Charney Laurence NeilDirector	Sale at price 54.96 per share.	5K	$274.80K
Aug 6, 2026	Charney Laurence NeilDirector	Stock Gift at price 0.00 per share.	6K	—
Jan 28, 2026	Charney Laurence NeilDirector	Stock Gift at price 0.00 per share.	43.2K	—
Jan 7, 2026	Weiss Michael SChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	622K	—
Jan 7, 2026	Power Sean AChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	90K	—
Nov 23, 2025	Echelard YannDirector	Sale at price 32.57 per share.	5K	$162.85K
Nov 4, 2025	Weiss Michael SChief Executive Officer	Stock Gift at price 0.00 per share.	4.67M	—
Sep 10, 2025	Lonial SagarDirector	Sale at price 32.24 per share.	20.9K	$672.27K
Jun 12, 2025	Echelard YannDirector	Sale at price 36.94 per share.	10K	$369.40K
Jun 11, 2025	Charney Laurence NeilDirector	Stock Award(Grant) at price 0.00 per share.	21.4K	—
Jun 11, 2025	Echelard YannDirector	Stock Award(Grant) at price 0.00 per share.	14.7K	—
Jun 11, 2025	Hoberman KennethDirector	Stock Award(Grant) at price 0.00 per share.	14.7K	—
Jun 11, 2025	Hume DanielDirector	Stock Award(Grant) at price 0.00 per share.	14.7K	—
Jun 11, 2025	Lonial SagarDirector	Stock Award(Grant) at price 0.00 per share.	14.7K	—
Mar 16, 2025	Hume DanielDirector	Stock Gift at price 0.00 per share.	62.5K	—
Mar 9, 2025	Charney Laurence NeilDirector	Stock Gift at price 0.00 per share.	6K	—
Jan 28, 2025	Weiss Michael SChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	750K	—
Jan 28, 2025	Power Sean AChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	87.5K	—
Jan 5, 2025	Power Sean AChief Financial Officer	Sale at price 28.53 - 30.29 per share.	21.4K	$629.38K
Nov 11, 2024	Charney Laurence NeilDirector	Stock Gift at price 0.00 per share.	5K	—

13F

Investors Holding TGTX

latest 13F filings of 29 followed managers

Investors holding TGTX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$37.3M	0.05%	679.30K	+99%	Q2 2026
Bridgewater Associates · Ray Dalio	$23.6M	0.10%	429.90K	+38%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

TGTX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

TGTX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About TG Therapeutics, Inc.

Seasonality · TGTX

Insider Activity · TGTX

Congress Trades · TGTX

Investors Holding TGTX

Investors Holding TGTX

Congress Trades · TGTX

Insider Activity · TGTX

Seasonality · TGTX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About TG Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News